First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.83B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.59M
Average 0.43M
Returns on capital
First Tracks Biotherapeutics Inc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.8%
avg -41.8%
ROIC
-59.4%
avg -43.8%
ROA
-50.2%
avg -37.1%
Analysis
ROA is currently the strongest return metric at -50.2% versus its period average of -37.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel R. Faga | CEO, President & Director | USD 1.2M | 46 | — | — |
Paul F. Lizzul | Chief Medical Officer | USD 795.2K | 51 | 42.50K | 0.12% |
Carlos A. Garcia | Senior Vice President of CMC. | — | — | — | — |
Beth Mueller | Senior Vice President of Human Resources | — | — | — | — |
Cailin Sibley FACR | Senior Vice President of Translational Medicine | — | — | — | — |
Monique Da Silva | Senior Vice President of Corporate Affairs | — | — | — | — |
Nicole Greene | Senior VP & General Counsel | — | — | — | — |
Nick Montemarano | Vice President of Investor Relations | — | — | — | — |
Ajim A. Tamboli | Chief Financial Officer | — | 49 | — | — |
Benjamin Stone | Chief Business Officer | — | 35 | 42.50K | 0.12% |
Eric J. Loumeau | Secretary | — | 63 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$1.76M
Net Transaction Value
−$1.76M
Net selling
Most Active
Ware J. Anthony
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 2, 26Sep 2, 2026 | Ware J. Anthony Direct | Sell | $1.8M$1,758,145.35 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $1.76M over the last 12 months. That adds up to net selling of $1.76M. Ware J. Anthony was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does First Tracks Biotherapeutics Inc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about TRAX's management, answered from reported figures.
Who manages TRAX?
First Tracks Biotherapeutics Inc (TRAX) lists 11 active executives. The top listed executive is Carlos A. Garcia, Senior Vice President of CMC..
Are TRAX insiders buying or selling?
Recent insider activity shows net selling of $1.76M.
Continue the stock analysis
Jump to another research area for this company.